GlassScriptPhysician profile
Liza Vazquez
NPI 1700234085
$12,242.32
in general payments reported to CMS, 2019-2025
42 companies · $3,121 in 2025
The $3,121 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $310 · 2021: $1,682 · 2022: $634 · 2023: $2,346 · 2024: $3,634 · 2025: $3,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,709 · Education: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,708.77 |
| Education | $391.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,653.79 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Janssen Pharmaceuticals, INC | $1,651.79 | 2021-2025 | Darzalex, Erleada, Talvey |
| E.R. Squibb & Sons, L.L.C. | $1,131.99 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Amgen INC. | $884.83 | 2019-2025 | Xgeva, Lumakras, Kyprolis |
| Pbg Puerto Rico LLC | $846.68 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $791.46 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Abbvie INC. | $616.00 | 2019-2025 | Epkinly |
| Eli Lilly Export S.A. Puerto Rico Branch | $437.74 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Tempus Ai, INC | $366.78 | 2024-2025 | Xt Cdx |
| Sobi, INC | $313.76 | 2023-2025 | |
| Medtronic, INC. | $301.27 | 2021 | |
| Genentech USA, INC. | $283.80 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Janssen Biotech, INC. | $255.93 | 2021-2023 | Darzalex |
| Genzyme Corporation | $232.00 | 2021-2025 | |
| Bayer Puerto Rico INC. | $221.76 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $218.14 | 2019-2023 | Tukysa, Padcev |
| Incyte Corporation | $212.17 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $205.37 | 2024-2025 | Libtayo |
| Abbott Laboratories | $177.80 | 2022-2023 | Xience Skypoint, Xience Sierra |
| Astellas Pharma US INC | $143.98 | 2021-2023 | Padcev |
| Exelixis INC. | $122.86 | 2024-2025 | Cabometyx |
| Eisai INC. | $122.77 | 2020 | |
| Rigel Pharmaceuticals, INC. | $119.10 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pfizer INC. | $118.30 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $109.56 | 2024-2025 | |
| Puma Biotechnology, INC. | $103.11 | 2020-2025 | |
| Caris Mpi, INC. | $91.14 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $85.64 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $69.50 | 2022-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $52.68 | 2025 | Xpovio |
| Beigene USA, INC. | $49.75 | 2024 | Brukinsa |
| Pharmaand Gmbh | $42.74 | 2024-2025 | Rubraca |
| Gilead Sciences, INC. | $39.87 | 2024-2025 | Trodelvy |
| Tolmar, INC. | $30.45 | 2025 | Eligard, Rubraca |
| Beone Medicines USA, INC. | $24.53 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $20.86 | 2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $20.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.39 | 2021 | |
| Morphosys, US INC. | $16.78 | 2024 | Monjuvi |
| Organon LLC | $16.31 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.86 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liza Vazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.